Page last updated: 2024-09-04

cyc 202 and Leukemia, Myeloid

cyc 202 has been researched along with Leukemia, Myeloid in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Boddy, N; Burrows, F; Pallis, M; Russell, N; Seedhouse, C; Whittall, A	1
Chen, L; Chen, Z; Cheng, JQ; Ren, Y; Reuther, GW; Wang, HG; Woods, NT; Wu, J	1

Other Studies

2 other study(ies) available for cyc 202 and Leukemia, Myeloid

Article	Year
Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells. BMC pharmacology & toxicology, 2013, Jun-15, Volume: 14 Topics: Acute Disease; Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Azacitidine; Cell Line, Tumor; Cell Survival; Clofarabine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Flavonoids; Heterocyclic Compounds, 4 or More Rings; Humans; Leukemia, Myeloid; Piperidines; Purines; RNA Polymerase II; RNA, Neoplasm; Roscovitine; Sirolimus; TOR Serine-Threonine Kinases	2013
Shp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XL. The Journal of biological chemistry, 2007, Dec-14, Volume: 282, Issue:50 Topics: Amino Acid Substitution; Apoptosis; bcl-X Protein; Benzopyrans; Cell Line; Cell Survival; Chlorpropamide; Chromones; Down-Regulation; Elafin; Enzyme Activation; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Leukemia, Myeloid; MAP Kinase Signaling System; Mitochondria; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Morpholines; Mutation, Missense; Myeloid Cell Leukemia Sequence 1 Protein; Myeloid Progenitor Cells; Neoplasm Proteins; Nitriles; Oncogene Protein p21(ras); Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Purines; Roscovitine; Up-Regulation	2007

Article

Year

Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells.

BMC pharmacology & toxicology, 2013, Jun-15, Volume: 14

Topics: Acute Disease; Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Azacitidine; Cell Line, Tumor; Cell Survival; Clofarabine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Flavonoids; Heterocyclic Compounds, 4 or More Rings; Humans; Leukemia, Myeloid; Piperidines; Purines; RNA Polymerase II; RNA, Neoplasm; Roscovitine; Sirolimus; TOR Serine-Threonine Kinases

2013

Shp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XL.

The Journal of biological chemistry, 2007, Dec-14, Volume: 282, Issue:50

Topics: Amino Acid Substitution; Apoptosis; bcl-X Protein; Benzopyrans; Cell Line; Cell Survival; Chlorpropamide; Chromones; Down-Regulation; Elafin; Enzyme Activation; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Leukemia, Myeloid; MAP Kinase Signaling System; Mitochondria; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Morpholines; Mutation, Missense; Myeloid Cell Leukemia Sequence 1 Protein; Myeloid Progenitor Cells; Neoplasm Proteins; Nitriles; Oncogene Protein p21(ras); Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Purines; Roscovitine; Up-Regulation

2007